Treatment of hyperlipidemia is the primary approved use of OM3FAs. In patients with triglycerides that are elevated (200-499 mg/dL) or very high (≥ 500 mg/dL), the AHA recommends 2-4 g/d of EPA or EPA plus DHA. The AHA concluded that prescription OM3FAs (eg, icosapent), as monotherapy or as an adjunct to other lipid-lowering agents, are an effective and safe option for reducing triglycerides at a dose of 4 g/d.
Learn more about hypertriglyceridemia.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Omega-3 Fatty Acids - Medscape - Aug 25, 2022.